×
About 743 results

ALLMedicine™ Agammaglobulinemia Center

Research & Reviews  250 results

Successful use of dupilumab to treat eczema in a child with X-linked agammaglobulinemia.
https://doi.org/10.1016/j.anai.2022.06.020
Annals of Allergy, Asthma & Immunology : Official Publica... Atwal S, Ong PY

Jul 1st, 2022 - Successful use of dupilumab to treat eczema in a child with X-linked agammaglobulinemia.|2022|Atwal S,Ong PY,|

Common Variable Immunodeficiency Workup
http://emedicine.medscape.com/article/1051103-workup

Jun 8th, 2022 - Laboratory Studies Common variable immunodeficiency (CVID) can be diagnosed after defective functional antibody formation is obtained. Usually, patients have decreased (not absent) serum IgA and IgG levels and, occasionally, decreased serum IgM le...

Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090539
Journal of Clinical Immunology; Lindahl H, Klingström J et. al.

May 11th, 2022 - Immunodeficient individuals often rely on donor-derived immunoglobulin (Ig) replacement therapy (IGRT) to prevent infections. The passive immunity obtained by IGRT is limited and reflects the state of immunity in the plasma donor population at the...

Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996444
The Journal of Allergy and Clinical Immunology; van Leeuwen LPM, GeurtsvanKessel CH et. al.

Apr 15th, 2022 - Patients with inborn errors of immunity (IEI) are at increased risk of severe coronavirus disease-2019 (COVID-19). Effective vaccination against COVID-19 is therefore of great importance in this group, but little is known about the immunogenicity ...

COVID-19 Vaccine Responses in PIDD Subjects
https://clinicaltrials.gov/ct2/show/NCT05321407

Apr 11th, 2022 - Individuals with primary and secondary antibody immunodeficiency are at higher risk for severe COVID-19 disease. Humoral immunity is thought to be the predominant protection against COVID-19, however mRNA vaccines have been shown to elicit both an...

see more →

Drugs  23 results see all →

Clinicaltrials.gov  6 results

COVID-19 Vaccine Responses in PIDD Subjects
https://clinicaltrials.gov/ct2/show/NCT05321407

Apr 11th, 2022 - Individuals with primary and secondary antibody immunodeficiency are at higher risk for severe COVID-19 disease. Humoral immunity is thought to be the predominant protection against COVID-19, however mRNA vaccines have been shown to elicit both an...

Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)
https://clinicaltrials.gov/ct2/show/NCT00161993

Aug 24th, 2021 - The purpose of this study is to determine the pharmacokinetics, efficacy and safety of Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution in subjects with primary immunodeficiency (PID) manifesting as hypo- or agammaglo...

Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT01441882

Apr 8th, 2021 - PRIMARY OBJECTIVES: I. To estimate the biologic target activity of dasatinib in CLL patients found to have pre-treatment in vitro dasatinib cytotoxicity (as defined by a >= 50% decrease in absolute lymphocyte count and/or bone marrow CLL count and...

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
https://clinicaltrials.gov/ct2/show/NCT02199496

Aug 24th, 2020 - The purpose of this study is to assess the safety/tolerability and efficacy of using ustekinumab in subjects with common variable immunodeficiency CVID or selective IgG subclass deficiency (functional agammaglobulinemia) who have associated sympto...

Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
https://clinicaltrials.gov/ct2/show/NCT02960399

May 31st, 2018 - Common variable immune deficiency (CVID), specific antibody deficiency (SAD), and X-linked agammaglobulinemia (XLA) are among the most common primary antibody deficiencies in which the mainstay of treatment is gammaglobulin replacement. The use of...

see more →

News  17 results

Byrd Discusses Optimizing Ibrutinib and Idelalisib in CLL
https://www.onclive.com/view/byrd-discusses-optimizing-ibrutinib-and-idelalisib-in-cll

Dec 20th, 2020 - John C. Byrd, MD In a presentation at the inaugural ASH Meeting on Hematologic Malignancies, John C. Byrd, MD, discussed what his clinical experience has revealed about the optimal use of ibrutinib (Imbruvica) and idelalisib (Zydelig) in chronic ...

Ibrutinib Represents "Transformative" Approach in CLL Treatment
https://www.onclive.com/view/ibrutinib-represents-transformative-approach-in-cll-treatment

Dec 5th, 2020 - Jennifer R. Brown, MD, PhD Jennifer R. Brown, MD, PhD, and John Byrd, MD, leading researchers in the emerging field of Bruton tyrosine kinase (BTK) inhibition in chronic lymphocytic leukemia (CLL) and other B-cell malignancies, discussed key ques...

BTK Inhibitor Success Puts Focus on Resistance Mechanisms
https://www.onclive.com/view/btk-inhibitor-success-puts-focus-on-resistance-mechanisms

Dec 5th, 2020 - Krithika Subramanian, PhD Less than 5 years after Bruton tyrosine kinase (BTK) inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged. The robust poten...

COVID-19 Outcomes Vary Widely in Patients With Primary Immunodeficiencies
https://www.staging.medscape.com/viewarticle/939374

Oct 20th, 2020 - NEW YORK (Reuters Health) - Clinical outcomes of COVID-19 in patients with primary immunodeficiency diseases range from mild illness to death, according to a small case series. "We were first surprised that we had only a few cases considering how ...

Dyspnea and Night Sweats in a 46-Year-Old Man
https://reference.medscape.com/viewarticle/732961_3

Jan 15th, 2020 - Which of the following is the most likely diagnosis? Your Peers Chose: Bruton agammaglobulinemia 0% Thymoma 0% Pheochromocytoma 0% Teratoma 0% Discussion The patient in this case was eventually diagnosed with thymoma. Symptoms from a thymoma or th...

see more →

Patient Education  1 results see all →